This document offers a comprehensive overview of a vital meeting titled “Mitigating Risks from Human Xylazine Exposure.” Hosted by the Reagan-Udall Foundation for the FDA, the meeting features expert speakers from prestigious organizations, including the White House Office of National Drug Control Policy and the U.S. Food and Drug Administration. The meeting’s agenda covers a range of critical topics, from assessing the current landscape of Xylazine exposure to discussing research needs and on-the-ground responses. It also delves into the clinical presentation of Xylazine and its concerning involvement in overdose deaths. With public health implications and actionable community recommendations, this document provides a valuable introduction to the in-depth PDF, making it a valuable resource for those seeking to address the challenges posed by Xylazine exposure.